Contraceptive access gaps driven by federal rollbacks, provider shortages, and stalled state legislation could be narrowed by letting trained pharmacists prescribe birth control independently.
|Articles|February 2, 2022
Daily OTC Pearl: Remifemin
Author(s)Saro Arakelians, PharmD
Remifemin provides an alternative to hormone replacement therapy for the treatment of menopausal symptoms.
Advertisement
OTC/Lifestyle Pearl of the Day: Remifemin
Indication: Remifemin is indicated for relief of menopause symptoms.
Insight:
- Dosing: 1 tablet twice a day, as recommended by the manufacturer.
- A clinically studied black cohosh extract can provide natural relief from hot flashes, night sweats, mood swings.
- Remifemin provides an alternative to hormone replacement therapy for the treatment of menopausal symptoms.
- It provides time-tested, estrogen-free relief.
- Remifemin provides up to a 70% reduction of hot flashes and effective relief for night sweats, irritability, mood swings, and occasional sleeplessness and anxiety.
Sources:
Advertisement
Related to this article
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
This article discusses a recent publication examining pharmacy access across Minnesota and explores the complex factors contributing to threatened community health access across the US.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
3
Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It
4
Biologic Stewardship: The Next Frontier for Health System Pharmacists
5